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AbstrACt
Introduction Falls and fall-related injuries are a serious 
cause of morbidity and cost to society. Environmental 
hazards are implicated as a major contributor to falls 
among older people. A recent Cochrane review found an 
environmental assessment, undertaken by an occupational 
therapist, to be an effective approach to reducing falls. 
However, none of the trials included a cost-effectiveness 
evaluation in the UK setting. This protocol describes 
a large multicentre trial investigating the clinical and 
cost-effectiveness of environmental assessment and 
modification within the home with the aim of preventing 
falls in older people.
Methods and analysis A two-arm, modified cohort 
randomised controlled trial, conducted within England, with 
1299 community-dwelling participants aged 65 years and 
above, who are at an increased risk of falls. Participants 
will be randomised 2:1 to receive either usual care or home 
assessment and modification. The primary outcome is 
rate of falls (falls/person/time) over 12 months assessed 
by monthly patient self-report falls calendars. Secondary 
self-reported outcome measures include: the proportion of 
single and multiple fallers, time to first fall over a 12-month 
period, quality of life (EuroQoL EQ-5D-5L) and health service 
utilisation at 4, 8 and 12 months. A nested qualitative study 
will examine the feasibility of providing the intervention 
and explore barriers, facilitators, workload implications and 
readiness to employ these interventions into routine practice. 
An economic evaluation will assess value for money in terms 
of cost per fall averted.
Ethics and dissemination This study protocol (including 
the original application and subsequent amendments) 
received a favourable ethical opinion from National Health 
Service West of Scotland REC 3. The trial results will be 
published in peer-reviewed journals and at conference 
presentations. A summary of the findings will be sent to 
participants.
trial registration number ISRCTN22202133; Pre-results.
IntroduCtIon 
Falls in older people are common and can 
have serious consequences. Approximately 
30% of people over the age of 65 years 
living in the community will have a fall 
each year.1 2 Around 85% of falls occur in 
the home.3 One-fifth of all falls are serious 
and require medical attention with 5% 
leading to a fracture.4 Fall-related fractures 
are a serious cause of morbidity and cost to 
society.5 Repeated falls commonly precipitate 
admission to institutional care and tend to be 
experienced by frail people in the older age 
range of 75 years and over.1 6 The number 
of falls is likely to increase due to an ageing 
population and will have a major impact 
on healthcare resource use, primarily due 
to hip fractures resulting from a fall. The 
importance of fall-related injuries has been 
recognised in the National Service Frame-
work (NSF) for Older People7 and in the 
National Institute for Health and Care Excel-
lence (NICE) Guidelines.8 The NSF calls for 
strengths and limitations of this study
 ► The largest randomised controlled trial in an English 
setting to assess the clinical and cost effectiveness 
of a home environmental assessment and modifica-
tion for falls prevention.
 ► Investigates the feasibility of recruiting participants 
from databases of participants previously assem-
bled while conducting cohort, falls prevention ran-
domised controlled trials.
 ► Hosts three ‘Studies within a Trial’, which will add to 
the evidence base about recruitment strategies and 
ways to minimise missing data within trials.
 ► Results will be generalisable to a community-dwell-
ing population of older people within England.
 ► Uses an unblinded, patient self-report primary out-
come measure; therefore, there is a possibility of 
reporting bias.
 o
n
 11 Septem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022488 on 10 September 2018. Downloaded from 
2 Cockayne S, et al. BMJ Open 2018;8:e022488. doi:10.1136/bmjopen-2018-022488
Open access 
health improvement plans to be devised that will reduce 
the burden of fall-related injuries.
It is well recognised that many falls result from an inter-
action between environmental hazards and a broad array 
of medical conditions and physiological impairments.9 
Environmental hazards are attributed by older people as 
primary factors in their falls and, thus, frequently cited 
in the literature as major contributors to falls. ‘Acci-
dent/environment’related factors were identified as the 
primary cause of just under one-third of falls in a review 
of 12 studies (mean of 31%, range 1%–53%, n=3628).6 
Talbot et al10 conducted a retrospective study and iden-
tified that ‘accident/environment’related factors were 
perceived by older people as the second most common 
cause of falls, with key environmental contributors identi-
fied as objects on floors, external forces and wet, uneven 
and icy surfaces.
The theoretical approach underpinning environ-
mental assessment and modification is the person–
environment–occupation (PEO) conceptual model of 
occupational therapy practice.11 This model posits that 
the person, environment and task being performed 
continually interact in ways that enhance or diminish 
a person’s occupational performance and that environ-
mental hazards are dynamic entities that occur through 
the interaction between these three elements. The PEO 
model underpins occupational therapy practice that 
aims to maintain, restore or create a balance between 
these elements.12
The latest Cochrane review in this area (updated 
September 2012)13 found that environmental assessment 
and modification was an effective approach to reducing 
falls (relative risk of falling 0.88; 95% CI 0.80 to 0.96). It 
also concluded that the effectiveness of an environmental 
intervention was increased if delivered by an occupational 
therapist (OT). Current NICE guidance suggests that 
‘older people who have received treatment in hospital 
following a fall should be offered a home hazard assess-
ment and safety intervention/modifications by a suitably 
trained healthcare professional’. However, at the time of 
setting up the study, there was no guidance with respect 
to environmental assessment for people living in the 
community who are at elevated risk of falling but have 
not yet received hospital treatment due to a fall. Indeed, 
there has only been one UK trial of environmental assess-
ment by an OT, which was a pilot study conducted by some 
of the authors.14  While this study showed no evidence 
of a difference between the randomised groups on the 
primary outcome of fear of falling, a statistically signif-
icant reduction was observed in the number of falls (a 
secondary outcome). Consequently, there is reasonable 
evidence to suggest OT delivered home hazard assess-
ment and modification can lead to a reduction in falls. 
This large, multicentre trial builds on this previous work 
and aims to undertake a high-quality, adequately powered 
trial to evaluate the clinical and cost-effectiveness of an 
environmental assessment and modification, delivered by 
an OT, for the prevention of falls.
MEthods And AnAlysIs
trial design
The Occupational Therapist Intervention Study (OTIS) 
study is a modified cohort,15 pragmatic, two-arm, open, 
randomised controlled trial (RCT) with an economic 
evaluation and nested qualitative study. The cohort RCT 
(cRCT) design was chosen to avoid some of the key poten-
tial biases that can occur in a pragmatic trial, namely, 
high attrition and patient preference effects. In a cRCT, 
patients are recruited initially into a cohort, and there is 
usually an outcome run-in period. Given that outcome 
attrition occurs largely at the first follow-up time point, 
this attrition is largely avoided if an eligibility criterion for 
the randomised phase is completion of outcomes during 
the run-in period.16 With respect to preference effects, 
although the control group are aware of the possibility of 
being offered an intervention (in this case occupational 
therapy), they are unaware of when the actual randomis-
ation occurs: this might avoid those biases, due to patient 
preference effects, which relate to timing of the offer 
of the intervention. In this study, the cRCT design was 
modified in that both intervention and control groups 
were told about the intervention prior to randomisation 
and that which group they would be in would be decided 
by chance/randomisation. In the cmRCT design, the 
process of obtaining patient information and consent 
aims to replicate that in real world routine healthcare, 
where patients are never told prospectively that their 
care options will be decided by chance. This approach 
partly replicates routine care in that the participant is not 
aware of when randomisation takes place and those in the 
control group are not aware of when they were formally 
allocated to be in the comparison group. Similarly, the 
intervention group are offered the intervention without 
having to face the possibility that once an offer has been 
made, that randomisation would withdraw the offer.
otIs main study aim
The main aim is to establish whether environmental 
assessment and modification delivered by an OT will 
lead to a reduction in the number of falls among those at 
elevated risk of falling living in the community.
otIs secondary aims
This includes:
1. Establishing the cost-effectiveness of OT delivered en-
vironmental assessment and modification.
2. Assessing the impact of the intervention on partici-
pants’ quality of life.
3. Exploring the barriers and facilitators of implement-
ing the trial’s findings among OT professionals and 
the wider community (eg, commissioners of services).
Participants
Participant recruitment
One thousand two hundred and ninety-nine participants 
will be recruited by one of the following methods (see 
figure 1).
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Database search of existing cohorts held by the York Trials Unit 
(YTU) and the Yorkshire Health Study
The YTU has assembled a cohort of participants who orig-
inally participated in either the REFORM,17 SCOOP18 
or CASPER19 trials and agreed to be contacted about 
future research studies run by the YTU. These studies 
recruited participants aged 65 years and over, from either 
routine National Health Service (NHS) podiatry clinics 
or GP practices. A database search of these cohorts and 
the Yorkshire Health Study cohort to identify partic-
ipants over the age of 65 years20 will be undertaken to 
identify participants living in the OTs’ catchment area 
(Yorkshire and North Lincolnshire), who will be eligible 
for an invitation mailing. Participants known to live in a 
residential or nursing home will be excluded from the 
mail out. Potentially eligible participants will be sent an 
invitation pack asking if they would like to participate 
in the study. The pack will contain an invitation letter, 
Figure 1 Flow chart of participants through the OTIS trial. GP, general practitioner; OT, occupational therapist; OTIS, 
Occupational Therapist Intervention Study; YTU, York Trials Unit.
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participant information sheet, consent form, screening 
questionnaire and a prepaid envelope. In some cases, the 
person receiving the invitation pack may decline partici-
pation in the study, but a family member or friend may be 
interested in taking part. In such cases, the original recip-
ient will be asked to pass on the research team’s contact 
details, so that the interested person can contact the study 
team.
GP practices and other services
To increase the generalisability of the study’s findings, 
participants will be recruited through GP practices in 
primary care. GP practices will be recruited to the study 
after a member of the study team or the local Clin-
ical Research Network has contacted the practice and 
explained the study and the participants’ involvement. A 
database search will be undertaken to identify commu-
nity dwelling men and women over the age of 65 who 
will be sent a recruitment pack. Patients known to have 
dementia or Alzheimer’s disease or who live in a residen-
tial or nursing home will be excluded from the mail out 
by the use of Read Codes (which are a coded thesaurus of 
clinical terms) and review of the patient’s address.
Opportunistic screening
Where there is capacity, opportunistic screening by other 
healthcare professionals (eg, GPs, Rapid Assessment 
Teams, chronic obstructive pulmonary disease nurses, 
Heart Failure Nurses, Community Matrons or NHS 
services (eg, ambulance services)) will take place. Poten-
tial participants will be given an invitation pack.
Advertising for participants
Radio, newspaper, faith magazine, social media or tele-
vision advertisements may also be used to publicise the 
study and encourage potential participants to get in 
touch with the researchers. Additionally, posters or flyers 
may be placed within the geographical area of recruiting 
sites in places such as supermarkets, libraries and commu-
nity centres.
Individuals identified via any of the four approaches 
described above who wish to take part in the study will 
be asked to return their completed consent form and 
screening questionnaire by post to the YTU. Researchers 
will assess the screening form for participant eligibility 
according to the study eligibility criteria. Participants 
deemed to be ineligible will be informed in writing. If the 
respondent is assessed as being ineligible because they 
have not had a fall within the past 12 months or do not 
report a fear of falling, but otherwise fulfil the eligibility 
criteria, they will be given the option to be rescreened in 
4–6 months’ time.
All eligible, consenting participants will be asked to 
complete a baseline questionnaire and monthly falls 
calendars by post. Participants who return a valid base-
line questionnaire and at least one falls calendar will be 
randomised into the trial. Participants can withdraw from 
the study at any point. The reason for withdrawal will 
not have to be declared; however, if provided, this will 
be recorded. Participants who do not wish to take part in 
the main study are not required to return any forms to 
the YTU.
Inclusion criteria
Participants will be eligible for the OTIS trial if they:
1. Are aged 65 years or over.
2. Are willing to receive a home visit from an OT.
3. Are community dwelling.
4. Have at least one of the following risk factors for a fall 
in the next 12 months: either one fall in the past 12 
months or report a fear of falling on their screening 
questionnaire.
Exclusion criteria
Participants will be ineligible for the OTIS trial if they:
1. Are unable to walk 10 feet today (3.05 m) even with the 
use of a walking aid.
2. Are unable to give informed consent, for example, due 
to Alzheimer’s disease or dementia.
3. Live in a residential or nursing home.
4. Are unable to read or speak English and have no friend 
or relative to translate/interpret for them.
5. Have had an OT assessment for falls prevention in the 
previous 12 months.
6. Are on a waiting list for an occupational therapy as-
sessment.
7. Have not returned at least one completed falls calen-
dar in the 3 months prior to randomisation.
randomisation
Participants will be enrolled into the study if they fulfil 
the eligibility criteria and provide written consent to 
take part in the study; they will then be randomised to 
either the intervention or control arm when they have 
returned a valid baseline questionnaire and at least one 
falls calendar within 3 months prior to the point of rando-
misation. Randomisation will be carried out using the 
YTU secure web-based computer randomisation service 
based on an allocation sequence generated by an inde-
pendent data systems manager, who is not involved in the 
recruitment of participants. Participants will be randomly 
allocated to either the control group or the intervention 
group in a 2:1 ratio in favour of the control group (to 
reduce costs). Up to 12 participants from a particular site 
will be randomised at a time in a single block according to 
when sites state they have capacity to undertake interven-
tion appointments and for how many participants. The 
allocation ratio used may go up to 3:1 in a block if the OTs 
have reduced capacity to carry out the assessment. The 
YTU will write to the participant’s GP informing them of 
study participation and to participants who are allocated 
to the intervention group.
sample size
We propose to recruit and randomise 1299 participants to 
the OTIS trial in a 2:1 ratio (ie, 866 to usual care and 433 
to intervention). This number allows for 10% attrition and 
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provides 90% power (using two-sided significance at the 
5% level) to show a difference in the percentage of partic-
ipants who experience at least one fall in the 12 months 
following randomisation from 60% in the control group 
to 50% in the intervention group, accounting for the 
unequal randomisation (StataCorp. 2013. Stata Statistical 
Software: Release V.13). In the REFORM trial, previously 
conducted by some of the authors, an absolute difference 
of 5% was observed in the percentage of participants expe-
riencing a fall (intervention group: 50%; control group: 
55%), with a lower confidence limit of 13%; therefore, 
the decision was made to power this trial for a 10% abso-
lute difference. In the event that sites are struggling with 
capacity to undertake assessments, we will consider using 
an allocation ratio of 3:1 (usual care to intervention) to 
reduce the number of participants they would have to see. 
If the final ratio was 3:1 (ie, 974 to the usual care and 325 
to the intervention), we would have 85% power under the 
same conditions. The primary outcome is actually a count 
variable (number of falls, while proportion of participants 
experiencing at least one fall over the 12 months is a key 
secondary outcome); however, powering a trial for count 
data is more complex and requires greater assumptions 
and so a binary approach to the sample size calculation 
has been taken here.
blinding
Control participants will be blinded to when the interven-
tion takes place; however, due to the nature of the inter-
vention, participants in the intervention group will not 
be blind. It is also not possible to blind members of the 
research team who are actively involved in the adminis-
tration of the study, the statistician or health economist. 
Data entry staff will be blind to group allocation.
trIAl IntErvEntIon
otIs trial usual care group
Participants will receive usual care from their general 
practitioner (GP) and other healthcare professionals, 
which may include referrals to a falls clinic. Participants 
will receive a falls prevention advice leaflet produced by 
Age UK (‘Staying steady’ published in June 2015) with 
their baseline questionnaire in the post. A group-specific 
newsletter will be sent to participants at 3 months postran-
domisation and 2 weeks before their 12-month follow-up 
questionnaire is due, informing them about study prog-
ress. All participants will receive a pen and £5 with their 
12-month follow-up questionnaire in recognition of their 
participation and to offset any incidental expenses associ-
ated with completing the questionnaires.
otIs trial intervention group
In addition to the usual care and falls prevention leaflet 
described above, participants allocated to the interven-
tion arm will be offered a home environmental assessment 
to identify personal fall-related hazards and behaviours. 
The assessment will be undertaken by a Health and Care 
Professions Council registered OT and will take approx-
imately 2 hours to conduct. If the assessment is too 
demanding for the participant, the appointment may be 
split over two visits. OTs will attend a 1-day face-to-face 
training session on how to conduct the assessment. This 
will be provided by either the researcher who carried out 
the pilot trial (AP) or two of the OT researchers (ShC and 
AD) who will be trained by AP to deliver the training in a 
standardised way.
The environmental assessment will begin with an initial 
discussion about the participant’s history of falling, life-
style, patterns of usage of areas in the home, risk-taking 
behaviour, strategies already adopted to reduce falls, envi-
ronmental changes already in place prior to the assess-
ment and functional vision. This will then be followed by 
the Timed Up and Go (TUG) test and an environmental 
assessment using the Westmead Home Safety (WeHSA) 
tool.21 The WeHSA was developed in Australia in 1997 
for older adults and consists of a 57-item standardised, 
valid and reliable checklist of fall hazards in the following 
domains: internal/external traffic ways, general/indoors, 
living area, seating, bedroom, toilet, bathroom, kitchen, 
laundry, mobility aid, footwear, pets, medication manage-
ment and safety call systems. The OT and the participant 
will move through the house together, and a functional 
assessment will be completed. Items on the checklist will be 
rated as either relevant (ie, deemed to be a hazard) or not 
relevant (ie, not deemed to be a hazard or not present). 
The OT will discuss any potential falls hazards identified 
by either the participant or the OT during the assessment 
and problem solve with the participant to engage them in 
identifying possible solutions. A list of recommendations 
will be agreed. If possible, any identified hazards will be 
removed. If required, the OT will make referrals to other 
agencies for equipment or a handyman for other minor 
modifications. They may also make recommendations 
for equipment that cannot be provided by social services, 
such as lightweight step ladders with handles and height 
adjustable rotary washing lines. In such cases, the OT 
will liaise with the client or a family member regarding 
purchase of such equipment. The OT will make a clinical 
judgement whether an additional home visit is required. 
Four weeks after the assessment, the OT or member of 
the OTIS research team will telephone the participant to 
check adherence to the recommendations.
treatment fidelity
Treatment fidelity will be assessed using the following 
combination of strategies.
Provider training
A standard face-to-face training package will be used to 
standardise provider training. Training sessions will be 
recorded where possible. A checklist will be used to docu-
ment whether all aspects of the training are covered when 
provided by different facilitators. OTs will have the option 
to additionally undertake an online training course.
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Delivery of treatment
An observational study will be undertaken over the course 
of the trial to assess how the treatment was delivered. An 
OT who delivered the intervention training will shadow 
OTs while they visit participants. A checklist will be used to 
record which elements of the intervention are delivered. 
We will purposively sample OTs for shadowing to ensure 
we select a sample of OTs who attended different training 
sessions and who delivered either several or few assess-
ments. Approximately 10 OTs will be observed. While 
this is a small number of observations involving approx-
imately half of the OTs delivering the intervention, if a 
greater number were undertaken, then the observation 
itself would become part of the intervention. Consent 
for an additional, observing OT to attend the home visit 
will be obtained from the participant. Participants will be 
able to decline the second OT attending the visit at any 
point during the process and will still be able to receive 
a home visit. Elements of fidelity will also be included in 
the qualitative interviews. A similar sampling strategy to 
that detailed above will be used.
Demonstration of adherence
In order to demonstrate adherence, completion rates of 
the individual items on the WeHSA will be summarised. 
In addition to this, an OT who was involved in teaching 
the delivery of the intervention will review the WeHSA 
data collected by the OT for each participant. Delivery of 
the treatment is tailored to individual participant’s clin-
ical need; therefore, assessment and recommendations 
will not be the same for all participants. However, a check-
list will be used to document whether the key elements 
had been covered during each of the consultations.
outCoME MEAsurEs
Primary outcome measure for the otIs trial
The primary outcome is the number of falls per participant 
over the 12 months from randomisation. A fall is defined as 
‘an unexpected event in which the participant comes to rest 
on the ground, floor or lower level’.22 Data will be collected 
via participant self-reported monthly falls calendars, on 
which participants will be asked to mark the number of falls 
they have on each day or indicate that they have had no 
falls that month. An explanation of what the researchers 
consider to be a fall will be included in the participant 
information sheet and on the falls calendars. If a partici-
pant is uncertain as to whether an event is classed as a fall, 
then they will be encouraged to ring the research team at 
the YTU to discuss. Participants who do not return their 
falls calendar within 10 days of the due date will be either 
telephoned or sent a letter by the YTU to obtain missing 
data. Participants will be given a Freephone number to ring 
during office hours to report any falls as soon as possible 
after the event and when it is safe and convenient to do 
so. Participants who ring to report a fall will be asked for 
further details. Participants who indicate on their falls 
calendar that they have sustained a fall will be telephoned 
by the research team for further information. Information 
collected during the telephone call will include: cause/
reason for fall and consequence of fall, for example, super-
ficial wound (bruising, sprain, cut and abrasions), frac-
tures (including type of fracture) and hospital admissions. 
Data collected from the 4-month, 8-month and 12-month 
follow-up questionnaires will include falls data and will be 
used for those participants who do not return their monthly 
falls calendars.
otIs trial secondary outcomes
All secondary outcomes will be self-reported by the partic-
ipant and collected via questionnaires at baseline, 4, 8 and 
12 months or by monthly falls calendars. They include: 
proportion of participants reporting at least one fall in the 
12 months from randomisation; proportion of participants 
reporting multiple (two or more) falls in the 12 months 
from randomisation; time to first fall from date of rando-
misation; health-related quality of life as measured by the 
EQ-5D-5L23; fracture rate; fear of falling as measured by the 
question ‘During the past 4 weeks have you worried about 
having a fall?’; and health service utilisation.
nested qualitative study
To inform potential large-scale implementation of occupa-
tional therapy environmental assessment, qualitative inter-
views will take place with key stakeholder groups involved 
in intervention delivery (OTs and those who have clinical 
lead/practitioner roles for falls prevention services). Data 
will be collected on the feasibility of routinely providing 
this intervention, barriers and facilitators to implementa-
tion, workload implications and readiness to employ this 
intervention into their regular falls prevention practice. 
Normalisation Process Theory24 will be used to guide data 
collection and to frame the analysis to understand how easy 
it is to implement these interventions into routine practice.
Fifteen OTs delivering the intervention in the trial and 10 
clinical leads who run falls prevention services/care of older 
people services from organisations involved in the trial and 
five external to the trial will be purposively selected. Partici-
pants will be invited to attend a telephone interview.
Adverse events
This study will record and report details of any adverse 
events (AEs) that are required to be reported to the Health 
Research Authority, that is, events that are related to taking 
part in the study and are unexpected. The AE reporting 
period begins as soon as the participant consents to be in 
the study and ends 12 months after they are randomised.
Details of any AEs will be recorded using a trial adverse 
event form. Serious adverse events (SAEs) reported by 
the OT should be reported within 48 hours of the OT 
becoming aware of the event or within 14 days for non-se-
rious events. A follow-up report will be completed if addi-
tional information becomes available.
For this trial, an SAE is defined as any untoward occur-
rence that:
a. Results in death.
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b. Is life threatening.
c. Requires hospitalisation or prolongation of existing 
hospitalisation.
d. Consists of a congenital anomaly or birth defect.
e. Is otherwise considered medically significant by the 
investigator.
An event is defined as ‘related’ if the event was due to 
the administration of any research procedure. Whereas 
an ‘unexpected event’ is defined as a type of event not 
listed in the protocol as an expected occurrence.
The relatedness of an event will be reviewed by the chief 
investigator and the Trial Steering Committee. Incidents 
of hospitalisations, disabling/incapacitating/ life-threat-
ening conditions, ageing-associated diseases (such as 
cancer, cardiovascular disease, diabetes, arthritis, osteo-
porosis and dementia) and other common illnesses such 
as depression, falls and deaths are expected in the study 
population due to the age of the cohort. Similarly, any 
hospitalisation that was planned prior to entry into the 
study or cannot be attributed to taking part in the study 
or prolongation of an existing hospitalisation due to 
social reasons will not be recorded as an SAE.
stAtIstICAl AnAlysIs
There are no planned interim analyses; therefore, the 
statistical analysis will be undertaken at the end of the 
trial and will be conducted using STATA V.15 or later. All 
analyses will be conducted on an intention-to-treat (ITT) 
basis, including all randomised patients in the groups to 
which they were originally allocated. Participant base-
line data will be summarised descriptively by group, for 
all those who have been randomised and for all those 
who are included in the primary outcome analysis by 
randomised arm. No formal statistical comparisons will 
be undertaken. Continuous measures will be reported as 
means and SD, while the categorical data will be reported 
as counts and percentages.
statistical analysis of the otIs primary outcome
The number of falls per person will be analysed using 
Poisson regression (or negative binomial regression, as 
appropriate) adjusting for gender, age, history of falling 
and the allocation ratio used to randomise the partici-
pant as fixed effects. The model will include an exposure 
variable for the number of months that the participant 
returned a monthly falls calendar. A sensitivity analysis 
will be conducted to account for potential clustering 
effects by the OT by assigning every randomised partic-
ipant an OT irrespective of group allocation. For inter-
vention participants, this will be the OT delivering their 
intervention, whereas for control participants, a counter-
factual therapist, that is, one that they could have seen 
had they been randomised to the intervention group, 
will be randomly assigned to them. Therapist will then 
be included as a random effect in the primary analysis 
model. Additionally, a Complier Average Causal Effect 
analysis to assess the impact of compliance on treatment 
estimates will be undertaken for the primary analysis.
secondary analysis
The following outcomes will be analysed by logistic regres-
sion adjusted for the same covariates as the primary anal-
ysis model: the proportion of participants who fall at least 
once over the 12-month period from the date of rando-
misation; the proportion of multiple fallers (two or more 
falls in the 12 months from randomisation); the propor-
tion of participants having at least one fracture over the 
12-month follow-up; the proportion of patients obtaining 
multiple fractures (from different events, if this occurs a 
sufficient number of times); and the proportion of partic-
ipants who report that they are worried about falling at 
12-month postrandomisation.
Fear of falling will also be analysed in its continuous 
form using a covariance pattern model incorporating 
all postrandomisation time points in the analysis and 
adjusting for baseline score, gender, age, history of falling, 
allocation ratio, treatment group, time and a treatment 
group-by-time interaction. The correlation of observa-
tions within patients over time will be modelled.
The time to the first fall will be derived as the number 
of days from randomisation until the patient reports 
having a fall as detailed in the participant’s falls calendars. 
Time between any subsequent falls will also be calculated. 
Participants who have not had a fall will be treated as 
censored at their date of trial exit, or date of last available 
assessment or 365 days/trial cessation, as appropriate. 
The proportion of patients yet to experience a fall will 
be summarised by a Kaplan-Meier survival curve for each 
group. Time to fall will be analysed using the Andersen 
and Gill method for analysing time to event data when 
the event can be repeated. The analysis treats each time 
to event or censoring as a separate observation. The data 
will be analysed by Cox proportional hazards regression 
using robust SEs to account for dependent observations 
by participant and adjusting for the same covariates as in 
the primary analysis model.
Adherence to the WeHSA and results of the TUG will 
also be summarised descriptively.
Subgroup analysis
The primary analysis will be repeated including an 
interaction term between the treatment allocation and 
whether or not a patient received care in a hospital 
(outpatient appointment, day case, Accident and Emer-
gency presentation or hospital admission) as a result of a 
fall in the 4 months prior to completion of the baseline 
questionnaire.
Missing data
The amount of missing data will be reported by trial arm. 
A comparison of the baseline characteristics of partic-
ipants who are included in the primary analysis will be 
undertaken to ensure that any attrition has not produced 
imbalance in the groups in important baseline covariates. 
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A logistic regression model will be used to predict non-re-
sponse (no falls data received postrandomisation) 
including all variables collected prior to randomisation. 
The primary analysis will then be repeated, including as 
covariates all variables found to be significantly predictive 
of non-response, to determine if these affect the param-
eter estimates and study conclusions.
Qualitative analysis
All interviews will be audio recorded digitally and tran-
scribed verbatim. Initially, following familiarisation 
with the data, the interview material will be organised 
according to analytical headings using a constant compar-
ison approach.25 Key themes will be identified that will 
then be contextualised in relation to the broader dataset 
and will be used to assist the interpretation of the trial 
result. For example, if the intervention is shown to be 
effective, we will use an Normalization Process Theory 
(NPT framework to facilitate the development of an 
implementation plan for integration of occupational 
therapy falls environmental assessment into routine 
practice. During the analysis, regular meetings will be 
held between the qualitative research team and project 
steering group to discuss emergent themes.
AE data
AE data will be summarised descriptively by randomised 
arm.
trial monitoring
A Trial Steering Committee and Data Monitoring and 
Ethics Committee will monitor the trial at least every 12 
months or more frequently if the committee requests. The 
role of this committee will include the review of all SAEs 
that are thought to be treatment related and unexpected.
Economic evaluation
The health economic evaluation aims to establish the 
cost-effectiveness of OT delivered environmental assess-
ment and modification in terms of preventing falls and 
assess the impact of the intervention on participants' 
quality of life. The economic analysis will be performed 
using individual patient level data on an ITT basis. The 
analytical approach will take the form of cost-effective-
ness and cost–utility analyses. The cost-effectiveness 
approach will assess value for money in terms of cost per 
fall averted, and the cost–utility analysis will assess cost per 
quality-adjusted life-year (QALY) gained. The perspective 
for both analyses will be that of the UK NHS and personal 
social services, as well as secondary analyses undertaken 
from a societal perspective. Discounting for future cost 
and health benefit will not be undertaken given the time 
frame for the trial is 12 months after randomisation. The 
year of pricing will be set as the mid-year of the trial.
Health benefits associated with the treatments will 
be measured in terms of both estimates of the mean 
number of falls, corresponding to the main outcome of 
the trial, and mean QALYs, defined as a year lived with 
full health. In line with NICE recommendations,26 the 
EuroQol EQ-5D27 will be used to elicit patient utility 
values at different points in time and used to calculate 
QALYs for each patient, using the area under the curve 
approach.28 29 These utility values are used as ‘quality 
adjustment’ for each patient’s survival time. Specifically, 
the EuroQol EQ-5D-5L will be used.
Cost data will be collected for each patient regarding 
healthcare resource use, specifically within primary care 
and the community (ie, GP, nurse, physiotherapist and 
OT visits) and the hospital setting (ie, outpatient atten-
dances, day cases, inpatient stays and accident and emer-
gency attendances). Unit costs will then be applied to 
estimate the total cost per patient. Additional informa-
tion will be collected regarding intervention costs and 
private/personal expenses that feed into the societal 
perspective analysis (eg, activities of daily living equip-
ment and travel costs for healthcare attendances). Unit 
costs will be obtained from established costing sources 
such as NHS Reference Costs30 and PSSRU Unit Costs 
of Health and Social Care.31 Data on the cost and utility 
measures will be collected prospectively at baseline, 4, 8 
and 12 months via self-reported questionnaires.
Mean within-trial estimates of cost and health benefits 
will be estimated using regression methods, allowing 
for the correlation between costs and effects, as well as 
adjusting for covariates. The results will be presented as 
incremental cost-effectiveness ratios, where the differ-
ence in mean cost estimates between the two arms 
is divided by the difference in mean health benefit 
between the two arms. Findings will also be presented 
in terms of net health benefit.32 Multiple imputation 
methods will be used to handle missing data where 
needed.33
The uncertainty surrounding the decision to accept a 
treatment as the most cost-effective will be explored in 
cost-effectiveness acceptability curves (CEACs).34 These 
curves depict the probability of accepting a treatment as 
being cost-effective for a large range of willingness to pay 
values for an extra unit of health benefit. Sensitivity anal-
ysis will be conducted to explore the impact of underlying 
assumptions of the analysis and the range of unit costs on 
the cost-effectiveness results.
The main outcome of the trial, falls reduction, is asso-
ciated with a reduction in fractures. However, due to the 
restriction in the length of follow-up, the long-term effect 
in terms of the decreasing number of fractures might 
not be observed in the current trial. Therefore, a further 
analysis will explore the possible long-term impact of the 
trial, assuming that a falls reduction should also lead to a 
fracture reduction. A decision analytic model approach 
will be adopted to perform this task. The perspective will 
be the UK NHS and personal social services, with a life-
time time horizon whereby every participant in a hypo-
thetical cohort is followed up until the last participant 
dies. The hypothetical cohort will be constructed, based 
on the characteristics of the trial population, to estimate 
the QALY yield and cost saving of the long-term effect 
of the intervention. The model parameters that are not 
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collected in the trial will be extracted from the existing 
literature.
The model outputs will be the estimated expected mean 
costs, effectiveness and QALYs associated with each alter-
native treatment. Estimated total costs and outcomes will 
be discounted according to the latest health technology 
appraisal guidance.26 Uncertainty regarding cost-effec-
tiveness will be evaluated using probabilistic sensitivity 
analysis, where inputs into the analysis are defined as 
probability distributions that reflect uncertainty.35 The 
uncertainty surrounding the decision to adopt a given 
treatment option as a cost-effective treatment at different 
levels of willingness to pay will be represented in CEACs. 
The impact of assumptions undertaken in the analysis 
regarding the evidence over parameters or relating to the 
decision model (such as extrapolation) will be evaluated 
in sensitivity analysis, if possible.
PAtIEnt And PublIC InvolvEMEnt stAtEMEnt
Our patient representatives were identified from the cohort 
of participants who have taken part in previous studies run 
the members of the study team. They helped develop the 
design and conduct of the study by providing feedback on 
the grant application submitted to the funder. We have set 
up a Patient Involvement Group. This group gives advice to 
the trial team on the design and conduct of the trial. This 
included providing input into case report forms, informa-
tion sheets, participant newsletters and recruitment strate-
gies. They have agreed to help us disseminate our research 
findings by providing assistance with writing the plain 
language summaries and the research study findings letter 
we will send to participants who request it. A member of the 
group is also a member of the Trial Steering/Data Moni-
toring and Ethics Committee, where PPI is a standing item.
studies within trials
In addition to the main OTIS study, three ‘Studies within a 
Trial’ (SWATS) are being conducted.
Pen substudy
The aim of this substudy is to evaluate the effectiveness of 
including a pen with the trial invitation pack on recruit-
ment of participants to the OTIS study. Any patient identi-
fied in the GP mail out as eligible to receive an OTIS trial 
invitation pack will be entered into the pen substudy. Block 
randomisation will be used to allocate participants in a 2:1 
ratio in favour of the control group. Generation of the allo-
cation sequence will be undertaken independently by a 
researcher not involved with the production of the recruit-
ment packs. A single block the size of the number of partic-
ipants from each GP practice will be used. The intervention 
group will receive a pen with the YTU logo/details on it; the 
control group will not receive a pen at the point of being 
invited to take part in the study. The primary outcome is 
the proportion of participants who go on to be randomised 
to the OTIS trial. Secondary outcomes include: the propor-
tion of participants who return a screening form; time to 
return screening form; the proportion of participants who 
fulfil the eligibility criteria apart from the criterion relating 
to falls within past 12 months or fear of falling; the propor-
tion of participants who are eligible for randomisation; 
and the proportion of participants who remain in the trial 
at 3 months postrandomisation. Categorical data will be 
compared using logistic regression and time to response via 
a Cox proportional hazards model.
Invitation letter substudy
The aim of this substudy is to evaluate the effectiveness of 
writing the potential participant’s name by hand on the 
invitation letter, versus printing their name, on the recruit-
ment rate to the study. Participants will be eligible for this 
substudy if are they due to be sent an invitation pack about 
the OTIS trial in the first mail out undertaken by the York-
shire Health Study. Block randomisation will be used to 
allocate participants in a 1:1 ratio to receive either a hand 
written name on the invitation letter (intervention group) 
or printed name on the invitation letter (control group). 
Generation of the allocation sequence will be undertaken 
independently by a researcher not involved with the produc-
tion of the recruitment packs. The primary outcome is the 
proportion of participants who go on to be randomised to 
the OTIS trial. Secondary outcomes include: the propor-
tion of participants who return a screening form; time to 
return screening form; the proportion of participants who 
fulfil the eligibility criteria apart from the criterion relating 
to falls within past 12 months or fear of falling; the propor-
tion of participants who are eligible for randomisation; 
and the proportion of participants who remain in the trial 
at 3 months postrandomisation. Categorical data will be 
compared using logistic regression and time to response via 
a Cox proportional hazards model.
text message substudy
The aim of this substudy is to evaluate the effectiveness of 
a personalised text message compared with a standard text 
message on postal questionnaire response rates. Partici-
pants who are due to be sent their 4-month follow-up ques-
tionnaire and who have provided a mobile phone number 
and consented to be contacted by text message will be 
randomised. Block randomisation will be used to allocate 
participants in a 1:1 ratio to receive either a personalised 
(intervention group) or a standard text message (control 
group) at the same time as they are due to receive their 
postal follow-up questionnaire (ie, 2–4 days after the ques-
tionnaire is sent). The randomisation will be stratified by 
main trial allocation. Generation of the allocation sequence 
will be undertaken independently by a researcher not 
involved with the delivery of the text messages.
The personalised text message will read, ‘OTIS Trial: 
[Title, surname of participant] you should have received a ques-
tionnaire in the post by now. Your answers are important; so please 
help by returning it as soon as you can. Thanks.’.
The standard text message will read ‘OTIS Trial: you 
should have received a questionnaire in the post by now. Your 
answers are important; so please help by returning it as soon as 
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you can. Thanks.’. The primary outcome is the proportion 
of participants in each group who return the questionnaire. 
Secondary outcomes include time to response, complete-
ness of response, whether a reminder notice is required 
and cost-effectiveness. Categorical data will be compared 
using logistic regression and time to response via a Cox 
proportional hazards model. All models will adjust for main 
trial allocation.
sample size for the sWAts
As is usual with an embedded trial within a trial, no formal 
power calculation will be undertaken for the pen and text 
message substudies, as the sample size will be constrained 
by the number of participants available to either mail out 
to or contact. We will, however, randomise 314 participants 
who are due to be mailed out by the Yorkshire Health Study 
an invitation pack about the OTIS trial. This sample size 
will allow us to detect a 10% difference in the percentage 
of participants who go on to be randomised (from 10% to 
20%) between the two groups at 80% power and a two-sided 
alpha level of 0.1.
EthICs And dIssEMInAtIon
Ethics
All participants will give written informed consent prior to 
entry to the study. Further consent will be obtained for the 
qualitative interviews and fidelity observations.
dissemination
The results of the study will be disseminated through 
high-impact peer-reviewed journals through national and 
international research conferences and occupational thera-
py-specific journals and newsletters. A short summary of the 
results will be sent to participants who request this at the 
end of the trial.
dIsCussIon
This study uses a modified cRCT design. The authors 
have previously conducted three cRCTs.36 Participants in 
these trials were recruited from either routine NHS podi-
atry clinics17 or from general practices.18 19 All were aged 
at least 65 years and over and therefore had an elevated 
risk of falling. One key feature of the cRCT design is the 
capacity to undertake multiple RCTs over time. A strength 
to this trial is that during the recruitment phase of the OTIS 
study, we will be able to test the feasibility of recruiting 
participants from these cohorts and determine whether it 
is a quick and cost-effective means to recruit participants. A 
further strength lies in the fact that in addition to the main 
OTIS trial, we have taken the opportunity to undertake 
three SWATs. The results of these studies will add a signifi-
cant contribution to the body of evidence about strategies 
to improve recruitment to trials and minimise the amount 
of missing data.
One potential limitation to the study is that some partic-
ipants with mild dementia and cognitive impairment may 
be included in the study. These participants may have a 
higher risk of falling. We have tried to exclude this group 
of participants at screening by collecting data on partici-
pant’s medical history. In addition, if the study team have 
any concerns about the ability of a participant to provide 
informed consent or outcome data during the course of 
the study, then this is discussed with either the participant, 
a family member (if the participant consents) or with the 
participant’s GP. Nevertheless, it is still possible that some 
participants with mild dementia and cognitive impairment 
may be included in the study that we are unaware of. Further 
limitations include the fact that the study uses unblinded, 
patient self-report primary outcome measure, so there is 
the possibility of reporting bias being introduced. Also, 
the results of the study will be generalisable to a communi-
ty-dwelling population of older people within England only.
Falls in older people are a major health problem. A recent 
Cochrane review found environmental assessment, under-
taken by an OT, to be an effective approach to reducing 
falls in older people. As far as we are aware, none of the 
trials included a cost-effectiveness evaluation within a UK 
setting. The OTIS protocol aims to evaluate the clinical 
and cost-effectiveness of an environmental assessment and 
modification for preventing falls in older people and will 
be the largest trial to evaluate this intervention in isolation. 
If the results of this study are found to be positive, then 
further research could be conducted to investigate whether 
the intervention could be delivered equally effectively by 
trained assessors. Alternatively, further research into the 
intensity of the intervention, that is, whether more home 
visits are more effective, could be undertaken.
trial status
Recruitment and follow-up are in progress. Recruitment to 
the study began in October 2015 and will continue until 
approximately summer 2018. Participants will continue to 
be followed-up until winter 2019.
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